Monitoring for Hepatotoxicity: What Is the Predictive Value of Liver "Function" Tests?

被引:73
作者
Senior, J. R. [1 ]
机构
[1] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Silver Spring, MD USA
关键词
DISEASE; SURVEILLANCE; TUBERCULOSIS; TROGLITAZONE; INJURY; SERUM;
D O I
10.1038/clpt.2008.262
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug-induced liver injury (DILI) is a major reason drugs fail during development or are withdrawn from the market.(1) The ability to predict, detect, and avoid DILI through appropriate patient selection and effective monitoring has proved to be an elusive goal. Many approved drugs have labeling recommendations for serum enzyme monitoring intended to detect and prevent hepatotoxicity, but such monitoring is often seen as inconvenient, uncomfortable, costly, and inefficient by both patients and doctors, and thus monitoring recommendations are poorly followed, if at all. This review considers whether monitoring works to prevent DILI, whether monitoring recommendations are derived from data or opinions, and whether any better alternatives exist.
引用
收藏
页码:331 / 334
页数:4
相关论文
共 30 条
[1]   Screening in liver disease: Report of an AASLD Clinical Workshop [J].
Adams, PC ;
Arthur, MJ ;
Boyer, TD ;
DeLeve, LD ;
Di Bisceghe, AM ;
Hall, M ;
Levin, TR ;
Provenzale, D ;
Seeff, L .
HEPATOLOGY, 2004, 39 (05) :1204-1212
[2]   Drug-induced liver injury:: An analysis of 461 incidences submitted to the Spanish Registry over a 10-year period [J].
Andrade, RJ ;
Lucena, MI ;
Fernández, MC ;
Pelaez, G ;
Pachkoria, K ;
García-Ruiz, E ;
García-Munoz, B ;
González-Grande, R ;
Pizarro, A ;
Durán, JA ;
Jiménez, M ;
Rodrigo, L ;
Romero-Gomez, M ;
Navarro, JM ;
Planas, R ;
Costa, J ;
Borras, A ;
Soler, A ;
Salmerón, J ;
Martin-Vivaldi, R .
GASTROENTEROLOGY, 2005, 129 (02) :512-521
[3]  
AWAPARA J, 1952, J BIOL CHEM, V194, P497
[4]   Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: Results from the European postmarketing surveillance program [J].
Beghetti, Maurice ;
Hoeper, Marius M. ;
Kiely, David G. ;
Carlsen, Joern ;
Schwierin, Barbara ;
Segal, Eleanor S. ;
Humbert, Marc .
PEDIATRIC RESEARCH, 2008, 64 (02) :200-204
[5]   Outcome and prognostic markers in severe drug-induced liver disease [J].
Björnsson, E ;
Olsson, R .
HEPATOLOGY, 2005, 42 (02) :481-489
[6]   Brief communication: Severe hepatotoxicity of telithromycin: Three case reports and literature review [J].
Clay, KD ;
Hanson, JS ;
Pope, SD ;
Rissmiller, RW ;
Purclum, PP ;
Banks, PM .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (06) :415-420
[7]  
DAVIDSON CS, 1978, NIH PUBLICATION, P114
[8]   Troglitazone-induced liver failure: A case study [J].
Graham, DJ ;
Green, L ;
Senior, JR ;
Nourjah, P .
AMERICAN JOURNAL OF MEDICINE, 2003, 114 (04) :299-306
[9]   TRANSAMINASE ACTIVITY IN HUMAN BLOOD [J].
KARMEN, A ;
WROBLEWSKI, F ;
LADUE, JS .
JOURNAL OF CLINICAL INVESTIGATION, 1955, 34 (01) :126-133
[10]  
KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991